Tran T H, Duckert F
Thromb Haemost. 1984 Oct 31;52(2):112-6.
A technique is described to completely remove antithrombin III (AT) from small amounts of human plasma by immunoaffinity chromatography on antibodies against human AT linked to Sepharose 4B. The level of heparin cofactor II (HCII) was not affected by the immunoadsorption. HCII activity was then determined by measuring the rate of human thrombin inhibition by 3 ways: a) activation with heparin in AT-free plasma, b) activation with dermatan sulfate in normal plasma and c) activation with dermatan sulfate in AT-free plasma. The normal range of HCII varied between 0.7-1.5 U/ml, as compared to a normal plasma pool containing by definition 1 U/ml. Highly significant correlations between assays as obtained from 40 normal plasmas proved the suitability of the 3 assays, although the progressive thrombin inhibition by AT, when not removed, contributed about one fifth to the thrombin inhibition by HCII in the presence of dermatan sulfate. There were also highly significant correlations between HCII activity and antigen, as determined by rocket immunoelectrophoresis using specific antibodies against HCII. Levels of HCII and AT were examined in 7 patients with hereditary AT deficiency and 7 patients with disseminated intravascular coagulation (DIC). In hereditary AT deficiency, whereas the AT activity was reduced by half, levels of HCII activity and antigen were in the normal range. In DIC, a parallel decrease of HCII and AT suggests that HCII may participate in the inhibition of thrombin released during DIC and thus provides an inhibitor reserve, once the AT level becomes subnormally low.
本文描述了一种通过在与琼脂糖4B偶联的抗人抗凝血酶III(AT)抗体上进行免疫亲和层析,从小量人血浆中完全去除抗凝血酶III(AT)的技术。肝素辅因子II(HCII)的水平不受免疫吸附的影响。然后通过三种方法测量人凝血酶抑制率来测定HCII活性:a)在无AT血浆中用肝素激活,b)在正常血浆中用硫酸皮肤素激活,c)在无AT血浆中用硫酸皮肤素激活。与定义为1 U/ml的正常血浆池相比,HCII的正常范围在0.7 - 1.5 U/ml之间。从40份正常血浆获得的检测结果之间具有高度显著的相关性,证明了这三种检测方法的适用性,尽管在存在硫酸皮肤素的情况下,未去除的AT对凝血酶的渐进性抑制约占HCII对凝血酶抑制作用的五分之一。使用针对HCII的特异性抗体通过火箭免疫电泳测定,HCII活性与抗原之间也具有高度显著的相关性。对7例遗传性AT缺乏患者和7例弥散性血管内凝血(DIC)患者的HCII和AT水平进行了检测。在遗传性AT缺乏症中,AT活性降低一半,而HCII活性和抗原水平在正常范围内。在DIC中,HCII和AT平行下降,表明HCII可能参与抑制DIC期间释放的凝血酶,因此一旦AT水平降至正常以下,HCII可提供一种抑制剂储备。